GT Biopharma GTBP Cash Flow Statement (2010-2026)

NASDAQ GTBP
$5.41 -1.90 (-25.99%)
At close: Oct 21, 2026 · 4:00 PM EDT
Reported Financials

GT Biopharma Quarterly Cash Flow Statement

Periods 64 quarters
Latest Mar 2026

GT Biopharma reported cash from operations of -$2.50M and free cash flow of -$2.50M for the quarter ended Mar 2026, down 13.5% year over year. This cash flow statement covers 64 quarters of results from Jun 2010 through Mar 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating Activities
Net Income
-4.86M-5.45M-18.02M-5.44M-2.98M-6.88M-5.58M-0.23M-1.99M-2.42M-2.96M-2.27M-3.71M-3.41M-3.78M-0.78M-30.17M8.30M-5.75M-2.83M
Depreciation and DepletionDep. & Depletion
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
Amortization of Deferred ChargesAmort. Deferred Charges
Depreciation & Amortization (CF)Dep. & Amort.
Share-based CompensationStock Comp.
0.10M0.12M0.01M0.00M0.00M0.38M0.05M0.05M
Gains from Sales and DivestituresGains Divest
Gains from Investment SecuritiesGains Investment
-0.48M0.50M0.17M-0.02M-0.01M0.06M0.04M0.03M0.01M0.00M0.00M0.00M
Asset Writedowns and ImpairmentWritedown
Other non-cash itemsOther Non-Cash
-9.35M10.00M-10.32M0.88M-0.01M-0.06M0.06M-3.43M-1.40M-0.49M-0.08M-0.66M-0.12M-0.10M0.07M-0.13M0.11M-0.23M0.00M-0.01M
Change in Working Capital
Change in ReceivablesChange Receivables
Change in InventoryChange Inventory
Change in Accured ExpensesChange Accured Exp.
-0.01M6.39M-0.84M-0.89M-3.53M3.23M-0.03M1.08M0.39M0.53M-1.35M0.12M1.00M1.17M-1.29M-0.33M-0.81M1.14M0.11M
Change in Other Operating AssetsOther Assets Change
-0.03M0.02M0.11M0.25M-0.23M-0.06M-0.10M-0.02M0.01M-0.01M0.04M0.00M-0.06M0.17M-0.06M0.01M0.21M-0.10M-0.50M-0.22M
Change in Other Operating LiabilitiesOther Liabilities Change
-0.01M-0.02M-0.03M-0.02M-0.03M-0.03M-0.03M-0.03M-0.03M
Other Working Capital ChangesOther WC Changes
0.03M-0.02M-0.11M-0.27M0.21M0.04M0.08M-0.01M-0.04M-0.02M-0.07M-0.02M0.06M-0.17M0.06M-0.01M-0.21M0.10M0.50M0.22M
Cash from OperationsCash from Ops.
-4.29M-3.93M-3.71M-5.22M-2.79M-2.92M-4.30M-2.91M-1.94M-1.96M-2.05M-4.16M-3.54M-2.74M-2.47M-2.20M-3.01M-3.68M-4.01M-2.50M
Investing Activities
Capital ExpendituresCapex
Sales of Property, Plant and EquipmentPP&E (Sale)
3.53M1.08M
Change in Property, Plant and EquipmentChange in PP&E
3.53M1.08M
Purchase of InvestmentsInvestments Purchased
6.99M
Sale and Maturity of InvestmentsInvestments Sold
3.53M
Change in Acquisitions & DivestmentsChange Acquisitions
2.99M0.03M7.51M-6.99M2.66M1.85M0.48M5.03M7.86M0.00M0.00M
Cash from Investing ActivitiesCash from Investing
2.99M3.53M1.08M0.03M7.51M-6.99M2.66M1.85M0.48M5.03M7.86M0.00M0.00M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
Long-Term Debt RepaymentsLT Debt Repayment
Non-Current Debt
Short-Term Debt issuancesST Debt Issuance
Current Debt
Net Debt Issuances and RepaymentsNet Debt Issuance
Change in Capital Stock
Common Stock IssuedStock Issued
16.24M0.14M6.27M0.62M0.44M4.44M0.58M
Net Shares Issued and RepurchasedNet Shares Issued
16.24M0.14M6.27M0.62M0.44M4.44M0.58M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
1.06M4.01M4.00M
Net Equity Issued and RepurchasedNet Equity Issued
16.24M0.14M6.27M0.62M0.44M1.06M8.45M4.58M
Dividend Payments
Dividends Paid - Common and PrefferdDiv Paid (Total)
0.14M
Other financing activitiesOther financing
Cash from Financing ActivitiesCash from Financing
16.24M0.14M0.00M6.27M0.62M5.88M0.98M8.31M4.58M
Additional items
Change in Cash
11.95M-29.82M-0.71M-1.68M-1.93M-2.89M3.21M-3.63M0.72M-0.12M-1.57M0.87M7.30M-2.74M-2.47M-1.59M2.86M-2.70M4.28M2.11M
Ending Cash Balance
39.51M9.68M8.97M7.29M5.36M2.47M5.67M2.05M2.77M2.65M1.08M1.95M9.25M6.51M4.04M2.46M5.32M2.62M6.91M9.02M
Free Cash FlowFCF
-4.29M-3.93M-3.71M-5.22M-2.79M-2.92M-4.30M-2.91M-1.94M-1.96M-2.05M-4.16M-3.54M-2.74M-2.47M-2.20M-3.01M-3.68M-4.01M-2.50M
Net Cash FlowNCF
11.95M-3.79M-0.71M-1.68M-1.71M-2.89M3.21M-3.63M0.72M-0.12M-1.57M0.87M4.32M-2.74M-2.47M-1.59M2.86M-2.71M4.29M2.08M
Interest Paid

GT Biopharma Cash Flow Statement API

Pull GT Biopharma's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=GTBP&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY